<DOC>
	<DOCNO>NCT00111917</DOCNO>
	<brief_summary>The goal research study test clinical effectiveness drug call infliximab ( Remicade ) chronic beryllium disease ( CBD ) . This drug may reduce tumor necrosis factor-alpha ( TNF-a ) , associate severe disease inflammation lung . Receiving infliximab may help symptom , may improve clinical test data normally order doctor , breathe test . Baseline follow-up test look improvement breathe test ( pulmonary function test ) , exchange oxygen lung ( exercise test ) , chest x ray , lung inflammation .</brief_summary>
	<brief_title>Beryllium Infliximab Study : Clinical Interventional Trial</brief_title>
	<detailed_description>Hypothesis : The central hypothesis study infliximab prove efficacious treatment chronic beryllium disease ( CBD ) , inhibit beryllium specific T cell proliferation cytokine production . Specific Aims : Specific Aim 1 : To determine clinical effectiveness infliximab chronic beryllium disease . The efficacy infliximab measure improvement arterial gas exchange , arterial alveolar oxygen gradient ( A-ad02 ) end exercise subject CBD remain symptomatic pulmonary impairment despite current treatment prednisone and/or methotrexate . Secondary outcome measure include change airflow , lung volume , diffuse capacity ( DLCO ) , profusion small opacity chest x-ray , dyspnea score , quality life questionnaire . Specific Aim 2 : To determine effect infliximab intermediate marker biological function CBD . In vitro study examine effect infliximab blood lung cell culture , measure decrease beryllium ( Be ) -stimulated lymphocyte proliferation ; decrease Be-stimulated cytokine production , include TNF-a , IFN-g , IL-2 ; alter Be-stimulated apoptosis macrophage lymphocytes . Research Design Methods : Since information available regard pharmacokinetics infliximab patient CBD , pharmacokinetic information available use infliximab similar inflammatory condition form basis select dose regimen protocol . Particularly , 5mg/kg dose use study , base dose selection use sarcoidosis protocol C0168T48 presently underway multi-center trial ( NJC IRB HS-1771 ) . This investigator initiate , 40 week , randomize , double-blind , placebo control study evaluate efficacy infliximab dose 5mg/kg , compare placebo , individual symptomatic CBD pulmonary involvement despite prednisone and/or methotrexate treatment . Infliximab placebo infuse week 0 , 2 , 6 , 12 , 18 , 24 include spirometry , lung volume DLCO . Approximately 20 participant enrol study National Jewish Medical Research Center 3:1 drug : placebo rate . The primary endpoint study change baseline test week 28 test A-adO2 end exercise 6 minute walk . At baseline evaluation , subject undergo full pulmonary function testing , blood draw beryllium lymphocyte proliferation test ( BeLPT ) , 6 minute walk , chest x-ray , quality life dyspnea questionnaire . Follow-up full pulmonary function testing , rest end exercise A-ad02 , pulse oximetry total distance ( workload ) achieve 6 minute walk , chest radiograph measure week 12 . Final outcome measurement ( baseline test ) , include bronchoscopy BAL , repeat week 28 . A follow-up appointment schedule week 40 ass patient ' general health , well measure rest end exercise A-ad02 pulse oximetry 6 minute walk , pulmonary function test , QOL/dyspnea scoring , chest radiograph interstitial lung opacity profusion score . The effect infliximab Be-stimulated immune response assess compare follow marker infliximab therapy : 1 . BeLPT blood lavage cell ( BAL ) ; 2 . Be-stimulated cytokine production BAL cell include TNF-a , IFN-γ , IL-2 ; 3 . Cell-specific apoptosis . The assay include unstimulated control , 100 mM BeSO4 , 100 mM Al2 ( SO4 ) 3 metal-salt control , PHA - lymphocyte proliferation control , infliximab control , infliximab + BeSO4 , infliximab + Al2 ( SO4 ) 3 . At day 4 , 5 , 6 Be exposure , well pulse DNA-specific precursor , 3H-TdR , incubated four hour , harvest glass fiber filter , liquid scintillation method use count . Results report stimulation index , ratio count per minute treatment group count per minute unstimulated group . To determine effect infliximab cytokine production , CBD BAL CBD PBMC stimulate Be 24 hour . ELISA use determine TNF-α , IFN-γ , IL-2 supernatant level . After 24 hour beryllium exposure , harvest supernatant perform ELISA test TNF-α , IFN-γ , IL-2 . In order determine infliximab cause increase lymphocyte macrophage apoptosis , CBD BAL cell culture 24 hour Be . Cells double stain CD4+ ( Th1 ) CD71+ macrophages versus intracellular activate caspase-3 , caspase-8 caspase-9 . These vitro study use assess potential biologic function infliximab immune mediate disease use disease model know antigen , CBD .</detailed_description>
	<mesh_term>Berylliosis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Ages 1880 . Noncaseating granulomas and/or mononuclear cell infiltrates demonstrate transbronchial lung biopsy . Abnormal blood and/or BAL BeLPT result . Current treatment prednisone and/or methotrexate specifically CBD condition , range dosage , least 6 month prior enrollment , stable dosage least 1 month prior first infusion . Moderate CBD severity , participant safely undergo bronchoscopy BAL include PaO2 &gt; = 50 mmHg room air ( Denver altitude 5,280 ft ) . Availability come back National Jewish Medical Research Center infusion , evaluation , followup . Capable provide informed consent . Willing able adhere study visit schedule protocolspecified procedure . Positive tuberculosis ( TB ) skin test upon screening : An intradermal tuberculin skin test must perform within 1 month prior first administration study agent . Any evidence TB . Considered ineligible accord TB eligibility assessment , screening , early detection reactivation rule . Positive pregnancy test . Women pregnant , nursing , plan pregnancy within one year screen Contraindications bronchoscopy BAL bleeding diathesis , PaO2 &lt; 50 mmHg room air , evidence acute infection , hemodynamic instability labile blood pressure , either &lt; 90/60 &gt; 160/110 , untreated coronary artery disease , medical reason subject able safely undergo bronchoscopy . Positive culture prior BAL indicate mycobacterial fungal infection . Positive special stain acid fast bacillus ( AFB ) fungi prior lung biopsy . Known atypical mycobacterium infection . Clinical evidence active infection time enrollment . Serious acute infection ( e.g. , viral hepatitis , pneumonia pyelonephritis ) previous 3 month . Have opportunistic infection ( e.g. , herpes zoster [ shingle ] , cytomegalovirus , Pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within 6 month prior screen . Documented HIV infection . Positive serology active hepatitis B C. A positive result indicate need referral consultant Hepatologist investigation support . Use investigational drug within 1 month prior screen within 5 half life investigational agent , whichever longer . Treatment therapeutic agent target reduce TNFa ( e.g . pentoxifylline , thalidomide , etanercept , etc . ) within 3 month screen . Prior use Enbrel® Humera® . Previous administration infliximab . Known allergy murine ( mouse ) product . Have current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , cardiac , neurologic , cerebral disease ( include demyelinate disease multiple sclerosis ) . Any history congestive heart failure , severe right sided heart failure , cor pulmonale . Presence transplant organ ( exception corneal transplant &gt; 3 month prior screen ) . Major surgery previous 3 month . Malignancy within past 5 year ( except squamous basal cell carcinoma skin treat evidence recurrence ) . History lymphoproliferative disease , include lymphoma , sign symptom suggestive possible lymphoproliferative disease , lymphadenopathy unusual size location ( nodes posterior triangle neck , infraclavicular , epitrochlear , perioaortic area ) , splenomegaly . Known recent substance abuse ( drug alcohol ) . Poor tolerability venipuncture lack adequate venous access require blood sample study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Beryllium Disease</keyword>
	<keyword>Berylliosis</keyword>
	<keyword>Beryllium Disease</keyword>
	<keyword>CBD</keyword>
	<keyword>Infliximab</keyword>
</DOC>